Want to see HK:2522 full AI Analyst Report?
Top Page
Jiangxi Rimag Group Co., Ltd. Class H
(2522)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$5.00
▼(-38.27% Downside)
Action:Reiterated
Date:08/27/26
The score is driven primarily by a moderate financial recovery (return to revenue growth and positive net income, with improved operating cash flow) offset by still-volatile profitability/free cash flow and rising debt since 2023. Technicals are mixed with only modest near-term support and a still-weak longer-term trend. Valuation is a headwind due to a negative P/E and no dividend yield data.
Positive Factors
Revenue Recovery
The return to revenue growth indicates that demand and operating activity recovered after the prior-year contraction. If maintained, renewed top-line expansion can improve fixed-cost absorption, support reinvestment, and provide a foundation for more durable earnings growth over the next several quarters.
Negative Factors
Rising Debt
Although equity remains above debt, the increase in borrowings since 2023 raises the company’s fixed financial obligations and reduces balance-sheet flexibility. Continued debt growth could make future capital allocation more constrained, particularly if profitability remains weak or operating cash flow becomes uneven.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The return to revenue growth indicates that demand and operating activity recovered after the prior-year contraction. If maintained, renewed top-line expansion can improve fixed-cost absorption, support reinvestment, and provide a foundation for more durable earnings growth over the next several quarters.
Read all positive factors
Jiangxi Rimag Group Co., Ltd. Class H (2522) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.21B
Dividend YieldN/A
Average Volume (3M)515.85K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth17.25%
EPS Growth25.51%
CountryHK
Employees1,390
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.01
Shares Outstanding343,563,570
10 Day Avg. Volume513,150
30 Day Avg. Volume515,850
Financial Highlights & Ratios
PEG Ratio-6.51
Price to Book (P/B)1.33
Price to Sales (P/S)3.03
P/FCF Ratio45.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.10B
Jiangxi Rimag Group Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Operating across China, Jiangxi Rimag Group Co., Ltd. specializes in providing medical imaging services. The company delivers a comprehensive suite of diagnostic imaging procedures, including MRI, CT, PET scans, X-rays, ultrasounds, and mammograph...
Jiangxi Rimag Group Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
68
Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 873.12M | 760.59M | 928.91M | 784.44M | 592.01M |
| Gross Profit | 295.24M | 277.33M | 332.60M | 236.95M | 175.19M |
| EBITDA | 223.50M | 169.30M | 256.20M | 207.86M | -147.44M |
| Net Income | 3.75M | -45.92M | 44.41M | 364.00K | -360.73M |
Balance Sheet | |||||
| Total Assets | 2.86B | 2.26B | 1.88B | 1.99B | 2.06B |
| Cash, Cash Equivalents and Short-Term Investments | 626.16M | 262.79M | 215.79M | 355.62M | 509.67M |
| Total Debt | 622.72M | 578.61M | 386.02M | 489.07M | 574.76M |
| Total Liabilities | 853.70M | 779.76M | 543.54M | 673.18M | 752.48M |
| Stockholders Equity | 1.99B | 1.46B | 1.29B | 1.27B | 1.27B |
Cash Flow | |||||
| Free Cash Flow | 57.74M | -298.75M | 104.92M | -73.46M | -124.68M |
| Operating Cash Flow | 177.44M | 12.74M | 201.44M | 198.17M | 18.00M |
| Investing Cash Flow | -334.20M | -327.05M | -117.07M | -251.54M | -151.03M |
| Financing Cash Flow | 524.60M | 383.74M | -235.72M | -96.45M | 452.92M |
Jiangxi Rimag Group Co., Ltd. Class H Technical Analysis
Positive
8.10
Price Trends
4.90
Positive
6.00
Negative
7.22
Negative
Market Momentum
0.08
Negative
59.41
Neutral
39.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2522, the sentiment is Positive. The current price of 8.1 is above the 20-day moving average (MA) of 4.94, above the 50-day MA of 4.90, and above the 200-day MA of 7.22, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 59.41 is Neutral, neither overbought nor oversold. The STOCH value of 39.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2522.
Jiangxi Rimag Group Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$1.78B | 9.07 | 6.97% | 9.52% | 3.85% | -1.23% | |
67 Neutral | HK$1.05B | 9.86 | 5.57% | 2.35% | 4.75% | ― | |
66 Neutral | HK$751.47M | 305.19 | 0.20% | 1.88% | 20.54% | -96.74% | |
56 Neutral | HK$1.18B | 86.19 | 0.48% | 0.99% | -3.26% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | HK$2.21B | -65.18 | -1.33% | ― | 17.25% | 25.51% |
* General Sector Average
HK:2522
Jiangxi Rimag Group Co., Ltd. Class H
5.38
-12.24
-69.47%
HK:1846
EuroEyes International Eye Clinic Limited
2.35
-0.56
-19.13%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.55
0.04
1.56%
HK:2279
Yonghe Medical Group Co., Ltd.
2.02
-0.62
-23.56%
HK:3309
C-MER Eye Care Holdings Limited
0.83
-1.03
-55.40%
HK:3886
Town Health International Medical Group Ltd.
0.18
-0.08
-30.92%
Jiangxi Rimag Group Co., Ltd. Class H Corporate Events
Jiangxi Rimag Group Completes Equity Acquisition and Expands Share Capital
Aug 28, 2026
Jiangxi Rimag Group Co., Ltd. has completed its previously announced acquisition of 100% equity interests in certain target companies, settling the consideration through a combination of transferring 5,736,500 treasury shares and issuing 49,435,50...
Jiangxi Rimag Group Boosts Revenue on Imaging Growth but Slips into Interim Loss
Aug 25, 2026
Jiangxi Rimag Group reported a 9.8% year-on-year rise in revenue to RMB513.0 million for the six months ended June 30, 2026, driven largely by strong growth in imaging solution services and a more than threefold increase in digital-intelligent ser...
Jiangxi Rimag reshapes governance team and secures listing rules waiver
Aug 25, 2026
Jiangxi Rimag Group Co., Ltd. has announced a change in its corporate governance team, with joint company secretary, authorised representative and process agent Ms. Zhang Xiao resigning effective 25 August 2026, citing no disagreement with the boa...
Jiangxi Rimag Schedules Board Meeting to Approve 2026 Interim Results and Consider Dividend
Aug 13, 2026
Jiangxi Rimag Group Co., Ltd. has scheduled a board meeting for August 25, 2026, to review and approve the interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider whether to recommen...
Jiangxi Rimag Steps Up On-Market Buybacks for Share Award Scheme
Jun 23, 2026
Jiangxi Rimag Group Co., Ltd. has initiated purchases of its own shares on the Hong Kong market through a trustee for use in its existing share award scheme funded by previously issued stock. Between October 2025 and the date of the announcement, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.